176 related articles for article (PubMed ID: 34571767)
1. Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population.
Jiménez Galán R; Prado-Mel E; Pérez-Moreno MA; Caballano-Infantes E; Flores Moreno S
Biology (Basel); 2021 Sep; 10(9):. PubMed ID: 34571767
[TBL] [Abstract][Full Text] [Related]
2. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice.
Ksienski D; Wai ES; Croteau N; Freeman AT; Chan A; Fiorino L; Brooks EG; Poonja Z; Fenton D; Geller G; Irons S; Lesperance M
Lung Cancer; 2019 Jul; 133():110-116. PubMed ID: 31200816
[TBL] [Abstract][Full Text] [Related]
4. Frontline pembrolizumab monotherapy for metastatic non-small cell lung cancer with PD-L1 expression ≥50%: real-world outcomes in a US community oncology setting.
Gadgeel SM; Rai P; Annavarapu S; Alam S; Goldschmidt JH; West HJ; Santorelli M; Martins RE
Front Oncol; 2024; 14():1298603. PubMed ID: 38525422
[TBL] [Abstract][Full Text] [Related]
5. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status.
Alessi JV; Ricciuti B; Jiménez-Aguilar E; Hong F; Wei Z; Nishino M; Plodkowski AJ; Sawan P; Luo J; Rizvi H; Carter BW; Heymach JV; Altan M; Hellmann M; Awad M
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753547
[TBL] [Abstract][Full Text] [Related]
6. First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.
Facchinetti F; Mazzaschi G; Barbieri F; Passiglia F; Mazzoni F; Berardi R; Proto C; Cecere FL; Pilotto S; Scotti V; Rossi S; Del Conte A; Vita E; Bennati C; Ardizzoni A; Cerea G; Migliorino MR; Sala E; Camerini A; Bearz A; De Carlo E; Zanelli F; Guaitoli G; Garassino MC; Ciccone LP; Sartori G; Toschi L; Dall'Olio FG; Landi L; Pizzutilo EG; Bartoli G; Baldessari C; Novello S; Bria E; Cortinovis DL; Rossi G; Rossi A; Banna GL; Camisa R; Di Maio M; Tiseo M
Eur J Cancer; 2020 May; 130():155-167. PubMed ID: 32220780
[TBL] [Abstract][Full Text] [Related]
7. ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data.
Dall'Olio FG; Maggio I; Massucci M; Mollica V; Fragomeno B; Ardizzoni A
Lung Cancer; 2020 Jul; 145():95-104. PubMed ID: 32417680
[TBL] [Abstract][Full Text] [Related]
8. Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab.
Friedlaender A; Metro G; Signorelli D; Gili A; Economopoulou P; Roila F; Banna G; De Toma A; Camerini A; Christopoulou A; Lo Russo G; Banini M; Galetta D; Jimenez B; Collazo-Lorduy A; Calles A; Baxevanos P; Linardou H; Kosmidis P; Mountzios G; Garassino MC; Addeo A
Acta Oncol; 2020 Sep; 59(9):1058-1063. PubMed ID: 32762415
[No Abstract] [Full Text] [Related]
9. Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.
Kawachi H; Tamiya M; Tamiya A; Ishii S; Hirano K; Matsumoto H; Fukuda Y; Yokoyama T; Kominami R; Fujimoto D; Hosoya K; Suzuki H; Hirashima T; Kanazu M; Sawa N; Uchida J; Morita M; Makio T; Hara S; Kumagai T
Invest New Drugs; 2020 Feb; 38(1):211-218. PubMed ID: 31784866
[TBL] [Abstract][Full Text] [Related]
10. Impact of Frailty on Outcomes of First-Line Pembrolizumab Monotherapy in a Real-World Population with Advanced Non-Small Cell Lung Cancer.
Jiménez Galán R; Prado-Mel E; Alvarez de Sotomayor M; Martin LA
Biology (Basel); 2023 Jan; 12(2):. PubMed ID: 36829469
[TBL] [Abstract][Full Text] [Related]
11. First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis.
Facchinetti F; Di Maio M; Perrone F; Tiseo M
Transl Lung Cancer Res; 2021 Jun; 10(6):2917-2936. PubMed ID: 34295688
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy Outcomes in Individuals With Non-Small Cell Lung Cancer and Poor Performance Status.
Veluswamy R; Hu L; Smith C; Ji J; Wang X; Wisnivesky J; Morillo J; Kale MS
JNCI Cancer Spectr; 2022 Mar; 6(2):. PubMed ID: 35603847
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status.
Grivas P; Plimack ER; Balar AV; Castellano D; O'Donnell PH; Bellmunt J; Powles T; Hahn NM; de Wit R; Bajorin DF; Ellison MC; Frenkl TL; Godwin JL; Vuky J
Eur Urol Oncol; 2020 Jun; 3(3):351-359. PubMed ID: 32423837
[TBL] [Abstract][Full Text] [Related]
14. Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan.
Morita R; Okishio K; Shimizu J; Saito H; Sakai H; Kim YH; Hataji O; Yomota M; Nishio M; Aoe K; Kanai O; Kumagai T; Kibata K; Tsukamoto H; Oizumi S; Fujimoto D; Tanaka H; Mizuno K; Masuda T; Kozuki T; Haku T; Suzuki H; Okamoto I; Hoshiyama H; Ueda J; Ohe Y
Lung Cancer; 2020 Feb; 140():8-18. PubMed ID: 31838169
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy with toripalimab for lung adenocarcinoma in a real-world patient with an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 4: a case report.
Xue Y; Zheng K; Xue J
Ann Palliat Med; 2021 Sep; 10(9):10114-10123. PubMed ID: 34628932
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic chemotherapy in advanced non-small cell lung cancer with poor performance status: A retrospective analysis from routine clinical practice.
Kancharla H; Gundu N; Pathak N; Vandidassane I; Khurana S; Pushpam D; Jain D; Kumar S; Pathy S; Mohan A; Malik PS
Curr Probl Cancer; 2020 Jun; 44(3):100550. PubMed ID: 31987521
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices.
Cowey CL; Liu FX; Black-Shinn J; Stevinson K; Boyd M; Frytak JR; Ebbinghaus SW
J Immunother; 2018; 41(2):86-95. PubMed ID: 29252916
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).
Tamiya M; Tamiya A; Hosoya K; Taniguchi Y; Yokoyama T; Fukuda Y; Hirano K; Matsumoto H; Kominami R; Suzuki H; Hirashima T; Uchida J; Morita M; Kanazu M; Sawa N; Kinoshita Y; Hara S; Kumagai T; Fujimoto D
Invest New Drugs; 2019 Dec; 37(6):1266-1273. PubMed ID: 31392549
[TBL] [Abstract][Full Text] [Related]
19. Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data.
Velcheti V; Hu X; Li Y; El-Osta H; Pietanza MC; Burke T
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205788
[TBL] [Abstract][Full Text] [Related]
20. First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study.
Amrane K; Geier M; Corre R; Léna H; Léveiller G; Gadby F; Lamy R; Bizec JL; Goarant E; Robinet G; Gouva S; Quere G; Abgral R; Schick U; Bernier C; Chouaid C; Descourt R
Cancer Med; 2020 Apr; 9(7):2309-2316. PubMed ID: 32022459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
